sulforaphane has been researched along with Parkinson Disease in 11 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have addressed this question in human dopaminergic neuroblastoma SH-SY5Y cells exposed to the parkinsonian toxin paraquat (PQ)." | 3.76 | Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. ( Bravo-San Pedro, JM; Cuadrado, A; Fuentes, JM; Gómez-Sánchez, R; González-Polo, RA; Lastres-Becker, I; Morán, JM; Niso-Santano, M; Ortiz-Ortiz, MA; Soler, G, 2010) |
| " Bioavailability studies also suggest the contribution of SFN metabolites, including erucin (ERN), to the neuroprotective effects of SFN." | 1.48 | Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease. ( Cantelli-Forti, G; D'Amico, M; Djemil, A; Hrelia, P; Morroni, F; Pruccoli, L; Sita, G; Tarozzi, A, 2018) |
| "Sulforaphane appears to be a promising compound with neuroprotective properties that may play an important role in preventing PD." | 1.43 | Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways. ( Cai, X; Cao, P; Chen, B; Chen, J; Cheng, X; Hu, Z; Lu, W; Shen, J; Sun, X; Wang, X; Wu, L; Yan, H; Yang, J; Yang, Y; Ye, J; Zhou, Q, 2016) |
| "Although the etiology of Parkinson's disease (PD) remains elusive, recent studies suggest that oxidative stress contributes to the cascade leading to dopaminergic (DAergic) neurodegeneration." | 1.40 | Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. ( Choi, JW; Han, SH; Hwang, O; Jang, BK; Kang, YG; Kim, DJ; Kim, JH; Kim, JW; Lee, J; Moon, MK; Park, KD; Song, HJ; Woo, SY; Yeon, SK, 2014) |
| "Parkinson's disease is an environmentally influenced, neurodegenerative disease of unknown origin that is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta of the brain." | 1.35 | Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells. ( Sens, DA; Shavali, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woo, SY | 2 |
| Kim, JH | 1 |
| Moon, MK | 1 |
| Han, SH | 1 |
| Yeon, SK | 1 |
| Choi, JW | 2 |
| Jang, BK | 1 |
| Song, HJ | 1 |
| Kang, YG | 1 |
| Kim, JW | 2 |
| Lee, J | 2 |
| Kim, DJ | 1 |
| Hwang, O | 1 |
| Park, KD | 2 |
| Kim, S | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Shin, SJ | 1 |
| Lee, C | 1 |
| Han, SM | 1 |
| Pae, AN | 1 |
| Han, G | 1 |
| Morroni, F | 2 |
| Sita, G | 2 |
| Djemil, A | 1 |
| D'Amico, M | 1 |
| Pruccoli, L | 1 |
| Cantelli-Forti, G | 2 |
| Hrelia, P | 2 |
| Tarozzi, A | 2 |
| Bao, B | 1 |
| Zhang, MQ | 1 |
| Chen, ZY | 1 |
| Wu, XB | 1 |
| Xia, ZB | 1 |
| Chai, JY | 1 |
| Yin, XP | 1 |
| Bolondi, C | 1 |
| Zolezzi Moraga, JM | 1 |
| Shah, SP | 1 |
| Duda, JE | 1 |
| Zhou, Q | 1 |
| Chen, B | 1 |
| Wang, X | 1 |
| Wu, L | 1 |
| Yang, Y | 1 |
| Cheng, X | 1 |
| Hu, Z | 1 |
| Cai, X | 1 |
| Yang, J | 1 |
| Sun, X | 1 |
| Lu, W | 1 |
| Yan, H | 1 |
| Chen, J | 1 |
| Ye, J | 1 |
| Shen, J | 1 |
| Cao, P | 1 |
| Niso-Santano, M | 1 |
| González-Polo, RA | 1 |
| Bravo-San Pedro, JM | 1 |
| Gómez-Sánchez, R | 1 |
| Lastres-Becker, I | 1 |
| Ortiz-Ortiz, MA | 1 |
| Soler, G | 1 |
| Morán, JM | 1 |
| Cuadrado, A | 1 |
| Fuentes, JM | 1 |
| Cook, AL | 1 |
| Vitale, AM | 1 |
| Ravishankar, S | 1 |
| Matigian, N | 1 |
| Sutherland, GT | 1 |
| Shan, J | 1 |
| Sutharsan, R | 1 |
| Perry, C | 1 |
| Silburn, PA | 1 |
| Mellick, GD | 1 |
| Whitelaw, ML | 1 |
| Wells, CA | 1 |
| Mackay-Sim, A | 1 |
| Wood, SA | 1 |
| Shavali, S | 1 |
| Sens, DA | 1 |
| Trinh, K | 1 |
| Moore, K | 1 |
| Wes, PD | 1 |
| Muchowski, PJ | 1 |
| Dey, J | 1 |
| Andrews, L | 1 |
| Pallanck, LJ | 1 |
11 other studies available for sulforaphane and Parkinson Disease
| Article | Year |
|---|---|
Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy.
Topics: Animals; Base Sequence; Cell Line; Disease Models, Animal; DNA Primers; Heme Oxygenase-1; Humans; Ma | 2014 |
Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.
Topics: Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Glutamate-Cysteine Ligase; Heme Ox | 2019 |
Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease.
Topics: Animals; Brassica; Cell Line, Tumor; Dopaminergic Neurons; Glutathione; Humans; Isothiocyanates; Mal | 2018 |
Sulforaphane prevents PC12 cells from oxidative damage via the Nrf2 pathway.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidant Response Elements; Antioxidants; Antiparkinson Age | 2019 |
Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease.
Topics: Actinin; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Caspase 3; Disease Models, A | 2013 |
Dietary modifications in Parkinson's disease: A neuroprotective intervention?
Topics: Animals; Antioxidants; Curcumin; Diet; Ergothioneine; Fragaria; Humans; Inflammation; Isothiocyanate | 2015 |
Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways.
Topics: Animals; Autophagy; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Glutathione; Humans; Is | 2016 |
Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis.
Topics: Animals; Apoptosis; Cell Line; Fibroblasts; Humans; Intracellular Signaling Peptides and Proteins; I | 2010 |
NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease.
Topics: Case-Control Studies; Cell Line; Female; Gene Silencing; Glutathione; Humans; Isothiocyanates; Male; | 2011 |
Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells.
Topics: Acetylcysteine; Anticarcinogenic Agents; Antioxidants; Arsenites; Cell Line, Tumor; Cell Survival; D | 2008 |
Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease.
Topics: Age Factors; Allyl Compounds; alpha-Synuclein; Animals; Animals, Genetically Modified; Cell Death; D | 2008 |